<DOC>
	<DOCNO>NCT01805999</DOCNO>
	<brief_summary>Chronic constipation phenomenon affect nearly 20 % population worldwide . Bulking agent ispaghula use treatment , half patient satisfied treatment . This highlight need good treatment option , require deep understanding gastrointestinal fate product . The GI MRI Research group University Nottingham develop new , non-invasive magnetic resonance imaging ( MRI ) techniques image gastrointestinal tract . In collaboration Ironwood Pharmaceuticals , investigator want understand gastrointestinal fate ispaghula treatment , also improve understand MRI parameter apply colon .</brief_summary>
	<brief_title>Ispaghula Colonic Water Content</brief_title>
	<detailed_description>The Rome III diagnostic criterion constipation must include two follow symptom &gt; 25 % time : straining , hard lumpy stool , sense incomplete evacuation , sensation anorectal obstruction/blockage , use manual manoeuvre facilitate defecation few 3 defecation per week . Treatments include osmotic laxative polyethylene glycol lactulose , stimulant laxative bisacodyl , secretagogues like sodium docusate , bulk agent psyllium . A good understanding mode action drug require , order provide good treatment chronic constipation . This somewhat challenging ; partly techniques available study intestinal content limit , unpleasant patient . The GI MRI group University Nottingham recently develop non-invasive , patient friendly MRI technique study colon . The technique allow assessment colonic volume , response meal , motility colon transit time ingested meal . This technique use demonstrate laxative effect mannitol subsequent reversal loperamide . Using MRI , water provide bright image T2-weighted image small bowel , signal rapidly lose reach colon . Pilot study suggest ispaghula ; highly hygroscopic form 1.5 % gel water , able maintain water form produce bright image T2-weighted scan colon . The GI MRI group want confirm pilot data perform placebo control trial ispaghula husk healthy volunteer , aim understanding mode action bulk agent improve understand MRI parameter apply colon . The aim achieve perform dose-finding mechanistic study healthy volunteer , assess response test meal take either placebo , 2 different dos ispaghula . Stools collect , assessed water content compare water content assess T2 weight MRI . The study validate current technique , optimise current MRI parameter provide insight mode action ispaghula .</detailed_description>
	<mesh_term>Psyllium</mesh_term>
	<mesh_term>Calcium polycarbophil</mesh_term>
	<criteria>Apparently healthy ; free GI disorder , age 18 65 year age Male female Body mass index ( BMI ) 18.0 30.0 kg m2 Suitable MRI scanning ( eg absence metal implant , infusion pump pacemaker assess MRI safety questionnaire No know gastrointestinal disease Not currently smoke No strenuous exercise great 10 hour per week No consumption 21 unit alcohol typical week No report participation another nutritional biomedical trial 3 month prestudy examination study . Inability discontinue medication likely alter GI transit Antibiotics 3 week prestudy examination Preexisting condition make need antibiotic likely study Previous gastrointestinal surgery ( exclude cholecystectomy appendectomy ) Known inflammatory bowel disease ; coeliac disease Subjects consider investigator unlikely comply study protocol Regular ( &gt; 3 times/week ) use Probiotics 3 week prior , study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ispaghula</keyword>
	<keyword>Gastrointestinal physiology</keyword>
	<keyword>Gastrointestinal response sugar</keyword>
	<keyword>MRI</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>stomach</keyword>
	<keyword>small bowel</keyword>
	<keyword>colon</keyword>
</DOC>